Abstract: Elevated intra-ocular pressure is reduced by administration directly to the eye of compounds that inhibit function of a Na+—K+—2Cl−2 cotransporter mechanism discovered in trabecular meshwork cells of mammalian eyes. These compounds are useful in treatment of diseases of the eye associated with elevated intra-ocular pressure, such as ocular hypertension and glaucoma. A screening method is provided to discover additional compounds with utility for lowering intra-ocular pressure by substantially inhibiting the Na+—K+—Cl−2 cotransporter mechanism in trabecular meshwork cells.

Abstract: Elevated intra-ocular pressure is reduced by administration directly to the eye of compounds that activate the Cl and K channels of the trabecular meshwork and/or Schlemm's canal endothelial cells of the mammalian eyes. Intra-ocular pressure may further be reduced by the co-administration of compounds that inhibit function of a Na+—K+—2Cl− co-transporter mechanism of the trabecular meshwork and/or Schlemm's canal endothelial cells. These compounds are useful in treatment of diseases of the eye associated with elevated intra-ocular pressure, such as ocular hypertension and glaucoma. A screening method is provided to discover additional compounds with utility for lowering intra-ocular pressure by substantially activating the Cl and K channels.

Abstract: Elevated intra-ocular pressure is reduced by administration directly to the eye of compounds that inhibit function of a Na+—K+—2Cl−2 cotransporter mechanism discovered in trabecular meshwork cells of mammalian eyes. These compounds are useful in treatment of diseases of the eye associated with elevated intra-ocular pressure, such as ocular hypertension and glaucoma. A screening method is provided to discover additional compounds with utility for lowering intra-ocular pressure by substantially inhibiting the Na+—K+—Cl−2 cotransporter mechanism in trabecular meshwork cells.

Abstract: Elevated intra-ocular pressure is reduced by administration directly to the eye of compounds that inhibit function of a Na+—K+—2Cl−2 cotransporter mechanism discovered in trabecular meshwork cells of mammalian eyes. These compounds are useful in treatment of diseases of the eye associated with elevated intra-ocular pressure, such as ocular hypertension and glaucoma. A screening method is provided to discover additional compounds with utility for lowering intra-ocular pressure by substantially inhibiting the Na+—K+—Cl−2 cotransporter mechanism in trabecular meshwork cells.

Abstract: Elevated intra-ocular pressure is reduced by administration directly to the eye of benzmetanide that inhibits function of a Na.sup.+ --K.sup.+ --2Cl.sup.-2 cotransporter mechanism discovered in trabecular meshwork cells of mammalian eyes. Benzmetanide is useful in treatment of diseases of the eye associated with elevated intra-ocular pressure, such as ocular hypertension and glaucoma.

Abstract: Elevated intraocular pressure is reduced by administration directly to the eye of compounds that inhibit function of a Na.sup.+ --K.sup.+ --2Cl.sup.-2 cotransporter mechanism discovered in trabecular meshwork cells of mammalian eyes. These compounds are useful in treatment of diseases of the eye associated with elevated intraocular pressure, such as ocular hypertension and glaucoma. A screening method is provided to discover additional compounds with utility for lowering intraocular pressure by substantially inhibiting the Na.sup.+ --K.sup.+ --Cl.sup.-2 cotransporter mechanism in trabecular meshwork cells.